Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024
October 15, 2024 07:30 ET
|
Tourmaline Bio, Inc.
Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November
Duck Creek Technologies Acquires Risk Control Technologies to Deliver Comprehensive Risk Management and Mitigation Solutions
October 10, 2024 11:34 ET
|
Duck Creek Technologies
Duck Creek Technologies Acquires Risk Control Technologies to Deliver Comprehensive Risk Management and Mitigation Solutions
State of the Cannabis Industry: Blank Rome Hosts Premier Conference Featuring Top Industry Leaders
October 07, 2024 14:37 ET
|
Blank Rome LLP
Boston, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Blank Rome LLP is set to host the eighth annual “State of the Cannabis Industry” conference, gathering leading professionals to analyze and discuss the many...
CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed’s strategy to cord blood-derived biologics through subsidiary, LongevityBank
October 03, 2024 07:00 ET
|
CYTOMED THERAPEUTICS LIMITED
SINGAPORE, Oct. 03, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary...
Safety Shot Spins Off Caring Brands Business with Plans to Issue a Dividend to Shareholders
September 26, 2024 09:15 ET
|
Safety Shot, Inc.
The Company is Divesting its Wellness Unit to Create Value for Shareholders and to Focus on Commercialization of its Safety Shot Dietary Supplement JUPITER, Fla., Sept. 26, 2024 (GLOBE NEWSWIRE) --...
ADR Ratio Change
September 19, 2024 16:30 ET
|
Biodexa Pharmaceuticals PLC
September 19, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) ADR Ratio Change Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical...
Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical stage RXR agonist for treatment of normal aging-related neurodegeneration, at the FASEB Science Research Conference on Cellular and Molecular Mechanisms of Brain Aging
September 18, 2024 11:07 ET
|
Io Therapeutics, Inc.
Io Therapeutics, Inc., presented on IRX4204 for treatment of brain aging, at the FASEB Conference on Cellular and Molecular Mechanisms of Brain Aging
Cybrexa Therapeutics Announces Positive Final Data at ESMO 2024 from Phase 1 Study of Peptide Drug Conjugate CBX-12 in Advanced Solid Tumors
September 16, 2024 06:30 ET
|
Cybrexa Therapeutics
Cybrexa Therapeutics Announces Positive Final Data at ESMO 2024 from Phase 1 Study of Peptide Drug Conjugate CBX-12 in Advanced Solid Tumors
Harvey Homan to Highlight MetasTx’s Game-Changing Approach to Cancer Treatment at PA Life Science Futures
September 12, 2024 06:58 ET
|
MetasTx LLC
MetasTx aims to revolutionize cancer treatment by targeting p21-activated kinase (PAK-1), a critical driver of metastasis in solid tumors.
Gamification Mobile Application in Healthcare Market is Expected to Hit US$ 31,168.1 Million by 2034 | Fact.MR Report
September 12, 2024 06:00 ET
|
FACT.MR
Rockville, MD, Sept. 12, 2024 (GLOBE NEWSWIRE) -- According to Fact.MR, a market research and competitive intelligence provider, the global gamification mobile application in healthcare market is...